stockrow
Friday 6 November 2026
Export KYMR’s income statement to Excel — free account
Kymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
132.01
3.89
+3.04%
Follow KYMR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 4 | 5 | — |
| (25.78%) | (27.09%) | (24.15%) | (27.29%) | ||
| (22.89%) | (24.35%) | (21.58%) | (24.36%) | ||
ROIC |
(29.80%) | (25.22%) | (26.72%) | (39.30%) | |
Return on Tangible Assets |
(37.46%) | (47.99%) | (42.44%) | (36.89%) | |
Average Days of Receivables |
0.00 | 0.00 | 69.52 | — | |
Free Cash Flow per Share |
(2.77) | (2.50) | (2.42) | (2.89) | |
Free Cash Flow |
(234.34) | (244.00) | (237.96) | (288.89) | |
Capital Expenditures |
(1.45) | (1.42) | (1.19) | (1.33) | |
| Other line items | |||||
Cash ROIC |
(9.65%) | (11.13%) | (10.81%) | (11.17%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 8.71 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
807.34% | 649.77% | 357.68% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
173.90% | 140.40% | 72.15% | 0.00% | |
Share Based Compensation of Revenue |
152.77% | 119.82% | 62.10% | 0.00% | |
Interest Coverage |
(944.32) | (1,000.35) | (1,054.75) | (1,367.86) | |
Operating CF/Net income |
0.75 | 0.77 | 0.79 | 0.82 | |
Depreciation/Fixed assets |
(0.01) | (0.02) | (0.03) | (0.02) | |
Capex/Depreciation |
2.56 | 1.78 | 1.13 | 2.21 | |
Revenue per Share |
0.46 | 0.53 | 1.07 | 0.00 | |
Operating CF per Share |
(2.76) | (2.49) | (2.41) | (2.87) | |
Capex per Share |
(0.02) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.04 | 0.03 | 0.01 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026